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E-mail address: bernie.creaven@ittdublin.ie (B.S. CThe condensation of substituted aromatic aldehydes with 7-amino-4-methyl-quinolin-2(1H)-one (1) has
lead to the isolation of quinolin-2(1H)-one derived Schiff bases (2–14). The copper(II) complexes (2a–
14a) of the ligands were also prepared, and together with their corresponding free ligands were fully
characterised by elemental analyses, spectral methods (IR, 1H and 13C NMR, AAS, UV–Vis), magnetic
and conductance measurements. The bidentate ligands coordinated to the copper(II) ion through the
deprotonated phenolic oxygen and the azomethine nitrogen of the ligands in almost all cases. X-ray crys-
tal structures of two of the complexes, 5a and 8a, confirmed the bidentate coordination mode. All of the
compounds were investigated for their antimicrobial activities against the fungus, Candida albicans, and
against Gram-positive and Gram-negative bacteria. The compounds were found to have excellent anti-
Candida activity but were inactive against Staphylococcus aureus and Escherichia coli. Selected compounds
(2–8 and 2a–8a) were also screened for their in vitro anticancer potential using the human hepatic car-
cinoma cell line, Hep-G2. Several derivatives were shown to be active comparable to that of cisplatin.
 2010 Elsevier B.V. All rights reserved.1. Introduction
Antimicrobial drug resistance is of increasing importance as the
phenomenon has considerable impact on human and animal
health. The prevalence of clinical drug resistance has unfortunately
increased significantly in recent decades due to the use and misuse
of antimicrobial drugs and many infectious diseases can no longer
be treated effectively with common anti-infective drugs. Antimi-
crobial resistance is not limited to bacterial species and in the
1990s resistance emerged to one of the most potent antifungal
agents, fluconazole [1]. Antifungal resistance is particularly prob-
lematic as diagnosis is often delayed and there are relatively few
antifungal treatments approved for use by the FDA. Over the last
number of years, our research group has been interested in devel-
oping compounds which have anti-Candida activity as Candida
albicans is associated with fungal infections that typically occur
in severely immunocompromised and/or critically ill patients [2].ll rights reserved.
ce, Institute of Technology
reaven).Quinolinones, an important class of heterocyclic compounds are
part of the quinoline alkaloid family and are also known for their
diverse biological activity [3]. Quinolinone heterocycles have
emerged as potential therapeutic agents and are the basis of many
medicinal drugs used in the treatment of heart failure, cancer and
inflammatory diseases [4]. They are also used as antibacterial,
antifungal, anti-inflammatory, antitubercular, anticancer, antineo-
plastic, anti-ischemic, anti-allergic, antihypertensive and anti-
ulcerative agents [5–9]. Recently, a novel series of quinolinones
have shown potent inhibitory activity against human immunodefi-
ciency virus type-1 (HIV-1) virus and also exhibited promising
activity against several non-nucleoside reverse transcriptase inhib-
itors (NNRTIs) [10]. One of the 6-functionalised quinolinone deriv-
atives was also reported to possess potent antitumor activity and is
undergoing human phase II/III clinical trails as an orally active
antitumor drug for the treatment of haematological and solid
tumours in the nanomolar range [8].
Schiff bases of azomethine nitrogen donor heterocyclic ligands
are well known due to their wide range of applications in pharma-
ceutical and industrial fields [11]. Transition metal complexes of
Schiff bases have attracted a lot of interest due to their potent
biological activities such as antifungal, antibacterial, anticancer
and herbicidal applications [12–16]. These studies have shown that
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crobial and anticancer activities of the ligands [12]. In addition,
more recently reports of quinolin-2(1H)-one-derived Schiff bases
and their metal complexes have emerged [17–22]. Several Schiff
base ligands derived from pyridine derivatives and their copper(II)
complexes have also been shown to inhibit tumour growth [23].
Our previous work has focussed on the synthesis and therapeu-
tic applications of a series of silver and copper complexes of cou-
marin-derived ligands [24–29]. More recently we have focused
our research efforts on the preparation of a series of coumarin-
and quinolin-2(1H)-one-triazole-derived Schiff bases and their
Cu(II) complexes [30,31]. In this paper, we report a new series of
quinolin-2(1H)-one derived Schiff base ligands and their copper
complexes and the assessment of their antimicrobial activities
against C. albicans, and against Gram-negative and Gram-positive
bacterial species. Our earlier studies had indicated that couma-
rin-derived copper(II) complexes had promising anticancer activ-
ity. Consequently, in the current study we have investigated the
activity of a number of novel copper(II) complexes using the
human-derived hepatic carcinoma cell line, Hep-G2.2. Experimental
2.1. Materials/instrumentation
All chemicals were purchased from Sigma–Aldrich were reagent
grade and used without further purification. Microanalytical data
were provided by the Microanalytical Laboratory, National Univer-
sity of Ireland, Belfield, and Dublin 4. Infrared spectra were re-
corded in the region of 4000–400 cm1, on a Nicolet Impact 410
Fourier-transform infrared (FTIR) spectrophotometer using OMNIC
software. All spectra were run as KBr discs. Melting point values
were recorded on a Stuart scientific SMP1 melting point apparatusC
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Fig. 1. General structure of a quinolin-2(1H)-one derived Schiff base with
numbering system used in this report.
Table 1
Ligand names, their relative substituents and positions of R groups for compounds (2–14)
Compound Name and Number
(7E)-7-(2,4dihydroxybenzylideneamino)-4-methylquinolin-2(1H)-one (2)
(7E)-7-(2-hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one (3)
(7E)-7-(2,3-dihydroxybenzylideneamino)-4-methylquinolin-2(1H)-one (4)
(7E)-7-(3-ethoxy-2-hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one (5)
(7E)-7-(2-hydroxy-3-methoxybenzylideneamino)-4 methylquinolin-2(1H)-one (6)
(7E)-7-(2-hydroxy-4-methoxybenzylideneamino)-4-methylquinolin-2(1H)-one (7)
(7E)-7-(3,5-di-tert-butyl-2-hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one (
(7E)-7-(5-bromo-2-hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one (9)
(7E)-7-(5-chloro-2-hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one (10)
(7E)-7-(5-fluoro-2-hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one (11)
(7E)-7-(2-hydroxy-5-iodobenzylideneamino)-4-methylquinolin-2(1H)-one (12)
(7E)-7-(3-hydroxy-4-methoxybenzylideneamino)-4-methylquinolin-2(1H)-one (13)
(7E)-7-(3-hydroxybenzylideneamino)-4-methylquinolin-2(1H)-one (14)and are uncorrected. Values were taken up to 300 C. All NMR
spectra were run on a JEOL JNM-LA300 FT-NMR (300 MHz 1H
and 75 MHz 13C) in d6-DMSO with 1H NMR spectra recorded in
the region of 5 ppm to 15 ppm from TMS (tetramethylsilane)
with a resolution of 0.18 Hz or 0.0006 ppm. All 13C NMR spectra
were recorded in the region 33 to 233 ppm from TMS with a
resolution of 0.008 ppm. Atomic absorption spectroscopy (AAS)
measurements were recorded on a Perkin–Elmer 460 AAS instru-
ment (emission wavelength 324.8 nm). Solid state magnetic
susceptibility measurements were carried out at room tempera-
ture using a Johnson Matthey Magnetic Susceptibility Balance with
[HgCo(SCN)4] being used as a reference standard. Molar conductiv-
ity was measured on a Systronic conductivity bridge with a
dip-type cell, using 4  103 M solution of complexes in DMSO.
UV–Visible (UV–Vis) spectra of the compounds in DMSO were
recorded on a Shimadzu UV-1601 spectrophotometer.2.2. Synthesis of 7-amino-4-methylquinolin-2(1H)-one (1)
7-Amino-4-methylquinolinone (1) was synthesised from 1,3-
phenylenediamine and ethyl acetoacetate according to a literature
procedure [32]. An off-white coloured product 1was obtained with
moderate yield (47%).2.3. Preparation of novel quinolin-2(1H)-one-derived Schiff base
derivatives (2–14)
All of the quinolin-2(1H)-one-derived Schiff base ligands (2–14)
were synthesised by an equimolar condensation reaction between
substituted aromatic aldehydes and 7-amino-4-methylquinolin-
2(1H)-one (1) in hot ethanol. A stirred suspension of 1 (2 mmol,
0.348 g) and the appropriate aromatic aldehyde (2 mmol) in hot
ethanol (40 mL) was refluxed for 4 h. On cooling to room temper-
ature, coloured precipitates (2–14) formed in good yields (>70%),
were filtered off and dried in a vacuum oven for two weeks. The
general structure of the ligands with the numbering system used
in this work is shown in Fig. 1 with detail of the exact structures
given in Table 1. All of the prepared ligands showed poor solubility
in polar and non polar solvents at room temperature and most of
them were only soluble in hot alcohols, acetonitrile, DMF and
DMSO. However, the halogen substituted compounds were soluble
only in hot DMSO and DMF. Analytical data for the ligands is given
in Tables 3–6..
R groups
R1 R2 R3 R4
OH H OH H
OH H H H
OH OH H H
OH OC2H5 H H
OH OCH3 H H
OH H OCH3 H
8) OH tBu H tBu
OH H H Br
OH H H Cl
OH H H F
OH H H I
H OH OCH3 H
H OH H H
Table 2
Crystal data and structure refinement of complexes 2a and 8a.
Empirical formula C38H40CuN4O9S (2a) C52H66CuN4O6 (8a)
Formula weight 792.34 906.63
T (K) 100(2) 100(2)
Wavelength (Å) 0.71073 0.71073
Unit cell dimensions
a (Å) 10.604(9) 10.07(3)
b (Å) 11.637(11) 10.907(2)
c (Å) 15.027(13) 22.926(6)
a () 101.661(15) 82.078(14)
b () 96.019(15) 78.592(13)
c () 95.741(18) 69.501(12)
V (Å3) 1792(3) 2306.5(10)
Z 2 2
Dcalc (Mg/m3) 1.468 1.305
Absorption coefficient
(mm1)
0.730 0.528
F (0 0 0) 826 966
Crystal size (mm3) 0.38  0.36  0.18 0.55  0.30  0.08
h Range for data collection () 2.24–28.00 0.91–21.82
Index ranges 13 6 h 6 13, 9 6 h 6 10,
15 6 k 6 15, 10 6 k 6 10,
18 6 l 6 19 0 6 l 6 23
Reflections collected 28 058 5389
Independent reflections 8562 5399
Completeness to h at 25.00 = 99.9% at 21.82 = 76.3%
Maximum and minimum
transmission
0.8798 and 0.7688 0.9590 and 0.7599
Refinement method Full-matrix least-
squares on F2
Full-matrix least-
squares on F2
Data/restraints/parameters 8562/5/500 5399/313/589
Goodness-of-fit (GOF) on F2 0.930 1.055
Final R indices [I > 2r(I)] R1 = 0.0550,
wR2 = 0.1284
R1 = 0.1162,
wR2 = 0.2853
R indices (all data) R1 = 0.1062,
wR2 = 0.1572
R1 = 0.1910,
wR2 = 0.3243
Largest difference in peak
and hole (e Å3)
0.505 and 0.801 0.843 and 0.637
Table 4
Selected IR and UV–Vis data (cm1) for the Schiff base ligands (2–14).
Ligand IR-spectra (mmax/cm1) UV–Vis
–C@O (lactam) –OH –C–O –CH@N kmax (nm)
2 1651 3464 1230 1575 280, 342, 355
3 1659 3457 1269 1601 297, 342, 356
4 1650 3388 1277 1604 276, 342, 355
5 1650 3458 1250 1599 297, 342, 355
6 1659 3457 1251 1600 296, 342, 355
7 1673 3456 1235 1603 278, 341, 356
8 1654 3448 1247 1608 290, 357
9 1655 3439 1276 1603 n/m
10 1659 3446 1280 1605 n/m
11 1692 3434 1285 1608 296, 342, 354
12 1652 3432 1280 1600 n/m
13 1660 3442 1277 1600 279, 356
14 1653 3455 1250 1613 267, 283, 355
n/m = Not measured due to poor solubility.
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Schiff base ligands (2a-14a)
All of the copper(II) complexes (2a–14a) were synthesised by
the following general procedure. Copper(II) acetate (0.125 mmol,
0.0227 g) (2a–4a, 6a–8a and 10a–14a) or copper(II) perchlorate
hexahydrate (2 mmol, 0.0463 g) (5a and 9a) was dissolved in
methanol (30 mL) and added drop-wise with stirring to a hot
methanolic solution of the appropriate ligand (0.25 mmol) to a fi-
nal volume of 60 mL. The resulting mixture was refluxed with stir-
ring for 5 h until a precipitate formed. Workup afforded coloured
complexes (2a–14a) in good yields (>70%). All of the complexes
were re-crystallised from an appropriate solvent system but suit-
able crystals were isolated only for complexes 2a and 8a. CrystalsTable 3
Analytical data for the series of quinolin-2(1H)-one derived Schiff base ligands (2–14).
Ligand Mw (g/mol) Yield (%) Empirical formula
2 294.30 72 C17H14N2O3
3 278.31 79 C17H14N2O2
4 294.30 74 C17H14N2O3
5 322.36 75 C19H18N2O3
6 308.33 73 C18H16N2O3
7 308.33 70 C18H16N2O3
8 390.52 60 C25H30N2O2
9 357.20 76 C17H13BrN2O2
10 312.75 78 C17H13ClN2O2
11 296.30 65 C17H13FN2O2
12 404.2 68 C17H13IN2O2
13 308.33 62 C18H16N2O3
14 278.31 61 C17H14N2O2suitable for X-ray diffraction measurements were obtained by the
slow diffusion of diethylether into a solution of the complex in a
binary solution of DMSO–MeOH. The analytical data for the com-
plexes is given in Tables 7 and 8.
2.5. X-ray crystallography
X-ray crystallographic studies were carried out at Heriot Watt
University, Edinburgh, United Kingdom. A single crystal is coated
in Paratone-N heavy oil then mounted on a Hampton Research
Cryoloop and placed in a cold stream of nitrogen gas (100 K) on a
Bruker Nonius X8 Apex2 CCD diffractometer running the APEX2
[33] software suite. Data collection consisted of, on average, 3000
frames from a combination of phi and omega scans. After unit cell
determination, the data were integrated using SAINT then scaled
with SADABS (TWINABS for 8a) before Space group determination with
XPREP, structure solution with XS and structure refinement with XL.
Pictures are prepared using the graphics program XP. The quality of
the datasets is checked using the IUCr checkcif facility. The crystal
of 8awas not single and very weakly diffracting and the anisotropy
of many atoms was restrained with the SHELXL [34] command ISOR.
Crystal data and structure refinement of copper(II) complexes 2a
and 8a are given in Table 3.
2.6. Biological testing
2.6.1. Anti-Candida susceptibility testing
The metal-free ligands (2–14) and their Cu(II) complexes
(2a–14a) were tested for their antifungal activity against a clinical
isolate of the fungal strain C. albicans (ATCC 10231) and a commer-
cially available antifungal drug, Amphotericin B. The screening wasFound (Calc) (%) M.P. (C)
C H N
69.07 (69.38) 4.78 (4.79) 9.36 (9.52) 280–282
73.12 (73.37) 5.03 (5.07) 9.96 (10.07) 278–280
69.28 (69.38) 4.42 (4.79) 9.29 (9.52) 298–300
70.62 (70.79) 5.60 (5.63) 8.68 (8.69) 268–270
69.90 70.12 5.06 (5.23) 9.09 (9.09) 288–290
69.60 (70.12) 5.18 (5.23) 9.07(9.09) 286–288
76.66 (76.89) 7.63 (7.74) 7.22 (7.17) 298–300
57.21 (57.16) 3.56 (3.67) 7.54 (7.84) >300
65.42 (65.29) 4.06 (4.19) 8.92 (8.96) >300
68.64 (68.91) 4.25 (4.42) 9.15 (9.45) >300
50.82 (50.51) 3.35 (3.24) 6.88 (6.93) > 300
70.01 (70.12) 5.02 (5.23) 9.22 (9.09) >300
72.57 (73.37) 5.05 (5.07) 10.09 (10.07) 290–292
Table 5
Characteristic 1H NMR chemical shift values (ppm), peak multiplicity and coupling constant J (Hz) for the synthesised ligands recorded in d6-DMSO.
Ligand (1H, s, H3) (1H, s) (1H, s) R1 (1H, s) R2 R3 R4 H19 (1H)
(vinyl) (CH@N) (NH)
2 6.35 8.83 11.60 13.28 (OH) 6.31, 1H, d, J = 2.20 10.37, 1H, s, OH 6.44, 1H, dd, J = 2.20, 8.44 7.50, d, J = 8.62
3 6.38 8.98 11.64 12.76 (OH) 6.93, 1H, m 7.03, 1H, m 7.42, 1H, m 7.70, dd, J = 1.83, 8.07
4 6.38 8.98 11.64 12.80 (OH) n/a (br, OH) 6.96, 1H, dd, J = 1.50, 7.89 6.79, 1H, pt, J = 7.70, 7.89 7.14, dd, J = 1.50, 7.0
5 6.38 8.98 11.65 12.89 (OH) 1.36, 3H, t, CH3, J = 7.0 4.05,
2H, q, OCH2, J = 7.0
7.14, 1H, dd, J = 1.31, 8.07 6.88, 1H,pt, J = 7.89, 7.89 7.26, dd, J = 1.50, 7.34
6 6.36 8.98 11.63 12.82 (OH) 3.61, 3H, s, OCH3, 7.13, 1H, dd, J = 1.50, 8.80 6.89, 1H, pt, J = 7.89, 8.07 7.24, dd, J = 2.02, 8.34
7 6.36 8.90 11.62 13.41 (OH) 6.51, 1H, d, J = 2.37 4.06, 3H, s, OCH3 6.57, 1H, dd, J = 2.38, 8.80 7.23, d, J = 8.62
8 6.36 9.03 11.66 13.79 (OH) 1.31, 9H, s, t-Bu 7.19, 1H, d, J = 1.70 1.43, 9H, s, t-Bu 7.44, 1H, d, J = 1.86
9 6.36 8.95 11.63 12.61 (OH) 6.95,1H, d, J = 8.80 7.54, 1H, dd, J = 2.57, 8.80 –Br– 7.91, d, J = 2.57
10 6.38 8.95 11.65 12.63 (OH) 6.99,1H, d, J = 8.80 7.42, 1H, dd, J = 2.57, 8.89 –Cl– 7.78, d, J = 2.75
11 6.30 8.94 11.64 12.31 (OH) 6.96, 1H, dda 7.25, 1H, dddb –F– 7.53, ddc
12 6.37 8.93 11.65 12.80 (OH) 6.83, 1H, d, J = 8.62 7.69, 1H, dd, J = 2.38, 8.71 –I– 8.07, d, J = 2.41
13 6.35 8.46 11.59 7.05 (1H) 9.40, 1H, s, OH 3.46, 3H, s, OCH3 7.08, 1H, d, J = 8.62 7.10, d, J = 8.62
14 6.35 8.55 11.62 7.07 (1H) 9.75, 1H, s, OH 6.92, 1H, m 7.31, 1H, m 7.37, d, m
a JH–H + 2JH–F = 4.58, 9.17.
b oJH–H + mJH–H + 1JH–F = 3.30, 8.99, 8.44.
c JH–H + 1JH–F = 12.27.
Table 6
Characteristic 13C NMR chemical shift values (ppm), for the ligands recorded in d6-DMSO.
C-2 C3 C-13 C-15 C-5 C-6 C-8 C-18 C-19
(C@O) (vinyl) (CH@N) (C–OH)
2 161.40 120.0 163.5 163.0 126.20 114.50 108.50 106.90 134.90
3 160.22 108.05 164.08 161.79 126.10 119.30 114.63 124.40 132.62
4 161.90 108.10 164.63 149.80 126.16 118.99 114.59 120.40 122.73
5 161.81 108.13 164.38 149.46 126.14 117.23 114.57 120.44 123.96
6 161.79 108.13 164.23 149.50 126.17 115.86 114.60 120.44 123.69
7 162.00 119.92 163.5 163.14 125.85 114.24 107.60 106.89 134.0
8 161.17 107.48 165.20 148.89 127.31 119.94 114.09 140.11 125.38
9 161.8 96.89 162.0 159.50 125.20 110.28 107.78 119.0 130.74
10 161.79 96.89 162.10 159.50 125.10 110.0 108.0 118.0 131.0
11 161.86 96.75 162.38 153.05 126.17 110.38 108.01 156.61a 116.69b
12 161.80 96.50 162.40 159.80 125.30 110.40 107.90 na 139.50
13 162.0 120.92 161.30 n/a 125.85 114.24 109.60 108.89 134.0
14 161.50 121.92 161.50 n/a 125.55 113.24 110.60 119.10 134.0
n/a = Not assigned
a d, 1JC–F = 67.2 Hz.
b d, 2JC–F = 93.6 Hz.
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protocol method (NCCLS) [35]. Isolates were grown for 24 h on
SDA plates at 37 C. Cells were suspended in sterile PBS (phosphate
buffered saline) to a concentration equal to a 1.0 McFarland stan-
dard (1  106) and further diluted (1:100) with minimal media
(MM). All compounds were prepared as 1% (v/v) solutions in DMSO
and each compound was tested in the range of 1–50 lg mL1.
Plates were incubated in an Anthos plate reader for 24 h at 37 C
with continuous shaking. Each compound was screened in tripli-
cate and three independent experiments were performed. The
stock solution of the compounds which were prepared initially at
lower concentration (0.001 g mL1) yielded a clear solution.
However, some of the compounds did not dissolve well in DMSO
and those compounds were tested as suspensions.
2.6.2. Antibacterial screening method
Only those complexes (2a–8a) and their respective ligands
(2–8) which showed good solubility in DMSO were tested for
their antibacterial activity against a Gram-negative bacterium
Escherichia coli and a Gram-positive bacterium Staphylococcus
aureus (clinically isolated from wound infections) for their antibac-
terial activity. The screening was carried out according to a litera-
ture reported method [24]. All media, buffers, and solutions used
during the course of this study were sterilised by autoclaving at
120 C for 15 min. Bacterial strains were grown for 24 h in nutrient
broth medium at 30 C and 200 rpm in an orbital incubator. Theabsorbance of the cultures was measured at 600 nm using a haem-
ocytometer and cultures were diluted to an optical density of 0.1.
The cell suspension (50 lL) was added to the wells of a 96 well
plate containing test compounds diluted in nutrient broth medium
in serial dilutions from 200 to 0.39 lM. Test compounds were ini-
tially prepared in 100% DMSO and then diluted with nutrient
broth, as above, so that the final concentration of DMSO in the cell
suspension was never more than 5% (v/v). Plates were incubated at
30 C for 24 h. The optical density was measured spectrophotomet-
rically (Dynex Technology) at 540 nm. Each compound was
screened in triplicate and three independent experiments were
performed. The MIC50 was defined as the concentration of test
compound which inhibited 50% visible growth of the strain in 24 h.
2.6.3. Assessment of anti-proliferate activity using MTT assay
Selected compounds (2–8 and 2a–8a) were screened for their
in vitro anticancer potential using the human-derived hepatic car-
cinoma cell line, Hep-G2. Cisplatin, the simple copper(II) salts, the
metal-free ligands (2–8) together with the copper(II) complexes
(2a–8a) were each dissolved in DMSO, diluted in culture media
and used to treat model cells at various drug concentrations for
periods of 96 h, prior to MTT assay. The maximum percentage of
DMSO present in any well was 0.25% (v/v). Cells were seeded in
sterile 96 well flat-bottomed plates (Sarstedt) at a density of
2.5  104 cells/mL and grown in 5% CO2 at 37 C. At the end of
the required incubation period, a miniaturised viability assay using
Table 8
Selected IR, UV–Vis and Molar conductivity data (cm1) for the Cu(II) complexes
(2a–14a).
Complex IR-spectra (mmax/cm1) UV–Vis Molar conductivity
–C@O –CH@N –C–O kmax (nm) KM [S mol1 cm2]
2a 1648 1585 1223 307, 390 1.27
3a 1666 1607 1247 341, 355, 390 0.51
4a 1664 1594 1266 342, 401 1.28
5a 1654 1604 1223 299, 408 14.45
6a 1665 1603 1245 296, 340, 401 1.6
7a 1644 1610 1226 303, 385 1.71
8a 1676 1612 1233 301, 425 0.4
9a 1665 1601 1264 n/m n/m
10a 1667 1603 1264 n/m n/m
11a 1667 1600 1268 n/m n/m
12a 1665 1598 1261 n/m n/m
13a 1652 1600 1259 n/m n/m
14a 1651 1598 1260 n/m n/m
n/m = Not measured due to poor solubility.
Table 7
Analytical data for the series of copper(II) complexes (2a–14a).
Complex Mw (g/mol) leff Yield Empirical formula Found (Calc) (%)
(B.M.) (%) C H N Cu
2a 650.14 1.69 81 C34H26CuN4O6 62.07 (62.81) 4.09 (4.03) 8.26 (8.62) 9.50 (9.77)
3a 618.14 1.61 72 C34H26CuN4O4 65.21(66.06) 4.22 (4.24) 8.62 (9.06) 9.95 (10.28)
4a 650.14 1.7 88 C34H26CuN4O6 62.20 (62.81) 3.99 (4.03) 8.41(8.62) 9.92 (9.77)
5a 905.15 1.77 73 C38H34 Cl2CuN4O14 51.05 (50.42) 4.13 (3.79) 6.20 (6.19) 6.74 (7.00)
6a 678.19 1.73 84 C36H30CuN4O6 64.67 (63.76) 4.67 (4.46) 8.27 (8.26) 9.05 (9.37)
7a 678.19 1.66 79 C36H30CuN4O6 63.34 (63.76) 4.29 (4.46) 8.03 (8.26) 9.10 (9.37)
8a 842.57 1.7 78 C50H58CuN4O4 70.45 (71.27) 6.67 (6.94) 6.39 (6.65) 7.10 (7.54)
9a 775.93 1.66 71 C34H24 Br2CuN4O4 51.92 (52.63) 3.03 (3.12) 6.89 (7.22) 7.95 (8.19)
10a 687.03 1.68 73 C34H24Cl2CuN4O4 59.28 (59.44) 3.59 (3.52) 7.86 (8.15) 8.94 (9.25)
11a 654.12 1.6 76 C34H24CuF2N4O4 62.76 (62.43) 3.80 (3.70) 8.45 (8.57) 9.94 (9.71)
12a 869.93 1.63 75 C34H24CuI2N4O4 47.10 (46.94) 2.93 (2.78) 6.16 (6.44) 7.55 (7.30)
13a 755.92 1.69 76 C34H22Cl4CuN4O4 54.12 (54.02) 3.06 (2.93) 7.59 (7.41) 8.14 (8.41)
14a 933.72 1.62 73 C34H22 Br4CuN4O4 43.89 (43.73) 2.47 (2.37) 5.97 (6.00) 6.64 (6.81)
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mide (MTT) was carried out according to the method described
by Mosmann [36]. In metabolically active cells, MTT is reduced
by the mitochondrial enzyme succinate dehydrogenase to form
insoluble purple formazan crystals that are subsequently solubi-
lised, and the optical density (OD) measured spectrophotometri-
cally. Drug-treated cells were assayed by the addition of 20 lL of
5 mg/mL MTT in 0.1 M phosphate buffer saline (PBS), pH 7.4.
Following incubation for 4 h at 37 C, the overlying medium was
aspirated with a syringe and 100 lL of DMSO was added to dis-
solve the formazan crystals. Plates were agitated at high speed to
ensure complete dissolution of crystals and OD was measured at
550 nm using an Anthos HT-II microtitre plate reader. Viability
was expressed as a percentage of solvent-treated control cells. This
assay had five replicates and each experiment was carried out on at
least three separate occasions. The IC50 was calculated and defined
as the drug concentration (lM) causing a 50% reduction in cellular
viability.3. Results and discussion
3.1. Synthesis and characterisation of novel quinolin-2(1H)-one
derived Schiff base ligands (2–14)
A series of quinolin-2(1H)-one-derived Schiff bases (2–14) were
synthesised by an equimolar condensation reaction between
substituted aromatic aldehydes and 7-amino-4-methylquinolin-
2(1H)-one in hot ethanol (Scheme 1). The ligands were character-
ised by melting point and IR, 1H NMR, 13C NMR, and UV–Visspectroscopies and CHN analysis and all relevant data is given in
Tables 3–6.
The IR spectra of the ligands have been summarised in Table 4.
The absence of the aldehydic carbonyl stretching bands and the
appearance of the characteristic azomethine mC@N bands at ca.
1600 cm1 confirmed the formation of the Schiff bases. The broad-
ness of the mOH band at ca. 3450 cm1 may be attributed to the
intramolecular hydrogen bond between CH@N(imine nitrogen) and
OH(phenolic) [37,38]. In all of the compounds, the stretching vibra-
tion of the lactam carbonyl was observed as a sharp band in the re-
gion of 1690–1650 cm1. Medium intensity bands in the range of
1285–1230 cm1 were also observed and were attributed to the
phenolic mC–O vibration [39]. The presence of additional bands be-
tween 1577 and 1400 cm1 are attributed mC@C bands of the aro-
matic rings.
The main 1H NMR signals for each of the ligands are shown in
Table 5. Formation of the ligands (2–14) was confirmed by the
absence of the NH2 proton signal at d 5.71 ppm assigned to the
starting material, 7-amino-4methyl-quinolin-2(1H)-one and the
presence of an azomethine proton signal at 8.46–9.03 ppm. In
addition, the disappearance of the aldehydic proton signal from
the corresponding starting aldehydes, the appearance of aromatic
proton signals in the region 6.51–7.90 ppm and an OH proton sig-
nal between 9.40–13.79 ppm further confirmed the formation of
the ligands. The signal corresponding to the hydroxyl group at po-
sition 15 (C15) was shifted downfield because of intramolecular
hydrogen bonding between it and the nitrogen of azomethine
(O–H  N=@CH) [40]. In ligands 2, 13 and 14, where there was
no possibility of hydrogen bonding with the azomethine nitrogen,
the corresponding signal was shifted upfield. Ligand 2 showed two
different OH proton signals at 13.28 (H-bonding) and 10.37 ppm
(no H-bonding) for positions 15 and 17, respectively. In the NMR
spectrum of 7, the OH proton signal was observed downfield at
13.41 ppm, whereas for 13 the OH signal appeared upfield at
9.40 ppm. The upfield shift was attributed to the lack of intramo-
lecular hydrogen bonding with the azomethine nitrogen in the lat-
ter compound. The positions of the proton signals compared
favourably to literature values of similar Schiff base compounds
derived from quinolin-8-amine, (pyridin-2-yl)methanamine and
3,5-di-t-butyl-4 hydroxyaniline reported by Creber et al. [41].
The main 13C NMR signals for the ligands are shown in Table 6.
The 13C NMR spectra of the Schiff base were characterised by the
presence of characteristic signals at ca. 164–140 ppm of the azo-
methine carbon (C@N, C-13), lactam carbonyl carbon (C@O, C-2),
C–OH (C-15), and C-4 (C–CH3) carbons and the upfield signals cor-
responding to vinyl (C-3) and the aromatic carbons (C-5, C-6, C-8,
C-18, and C-19). The spectra were further characterised by the ab-
sence of the aldehydic proton signal at ca. 190 ppm from the corre-
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Scheme 1. General reaction scheme for the synthesis of Schiff base ligands and their copper(II) complexes.
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of a methyl carbon signal (C-11) at ca.18 ppm. In all of the spectra
the azomethine (C@N) carbon was located at about 163 ppm and
the lactam carbonyl was observed at ca.161 ppm. 13C NMR signals
at C-5, C-19 and C-15 were affected by the deshielding character of
the imine group whereas the 13C NMR signal of the vinyl carbon at
C-3 position also appeared downfield because of its proximity to
the lactam carbonyl.3.2. Synthesis and characterisation of copper(II) complexes (2a–14a)
Ligands (2–14) were reacted in a 2:1 mole ratio with either
copper(II) acetate or copper(II) perchlorate hexahydrate in an
appropriate solvent to afford copper(II) complexes (2a–14a) of
the corresponding ligands (Scheme 1). All of the complexes were
characterised by IR, UV–Vis, magnetic moments, molar conductiv-
ity, X-ray crystallography where possible, and CHN analyses and
the data shown in Tables 7 and 8.3.2.1. IR spectra of copper(II) complexes (2a–14a)
Comparison of the infrared spectral data of complexes (Table 8)
and their corresponding ligands (Table 5) confirmed that complex-
ation had occurred as significant shifts in the bands of the azome-
thine group mCH@N, lactam mC@O, phenolic mOH and mC–O groups were
observed. The expected mode of interaction between the Schiff
base ligand and the copper(II) ion was via coordination of the cop-
per ion to the azomethine nitrogen group and the phenolic oxygen
[42]. The strong band at 1604–1575 cm1 assigned to m(C@N) in the
free ligand was shifted to either lower or higher wavenumber in
most of the complexes, indicating the participation of the azome-
thine nitrogen in the coordination [43]. The medium intensity band
at 1285–1230 cm1 assigned to m(C–O) in the free ligand was also
shifted to lower frequency (1268–1223 cm1) in the complexes.
The change in the intensity of this band confirmed the involvement
of the phenolic oxygen in the coordination. Moreover, the appear-
ance of additional weak bands in the region 485–425 and 585–
530 cm1 which were attributed to m(M–O) and m(M–N),
respectively further confirmed complexation [44].
In the spectra of complex 5a, bands at 1099 and 622 cm1 were
assigned to non-coordinated perchlorates counter anions [45–47]
and the presence of these ions was confirmed by elemental analy-sis and molar conductivity results. In contrast to the other com-
plexes isolated, 5a exhibited a sharp band at 3424 cm1 which
was attributed to the phenolic hydroxyl group. Therefore, it was
concluded that in complex 5a, the mode of coordination of metal
ion to the ligand was via the nitrogen of azomethine and the oxy-
gen atom of the phenolic groups, a coordination mode noted in
similar Schiff base complexes of Ni(II), isolated by Majumder
et al. [47].3.2.2. Magnetic susceptibility of copper(II) complexes (2a–14a)
The effective magnetic moment values (leff) of copper(II) com-
plexes were calculated using the formula leff = 2.84 (vcorr  T)1/2
B.M. The magnetic moment values of the complexes are given in
Table 7. The effective magnetic moments obtained for the com-
plexes are in the range of 1.60–1.77 B.M. which is consistent with
the presence of one unpaired electron [48]. Generally mononuclear
copper(II) complexes (those lacking of Cu–Cu interactions) exhibit
magnetic moments in the range 1.75–2.20 B.M. corresponding to
one unpaired electron (3d94s0), regardless of the stereochemistry
[21,49]. The observed magnetic moments values are within the ex-
pected range for mononuclear copper(II) complexes.3.2.3. Electronic spectra of copper(II) complexes (2a–8a)
The electronic spectral data in DMSO are given for ligands 2–8
and their respective Cu(II) complexes in Tables 5 and 8, respec-
tively. The spectra were not recorded for the complexes 9a–14a
which had poor solubility in DMSO. The electronic spectral data
of 2–8 exhibited two bands in the UV region around 276–305,
340–357 and their complexes (2a–8a) had an additional band at
ca. 385–425 nm. The bands at 276–300 nm were assigned to
p? p* intra ligand transitions that were localised on the conju-
gated system of the aromatic moieties [50–52]. The other absorp-
tion bands observed in the region of 340–357 nm were assigned to
the p? p* and n? p* electronic transitions of the azomethine and
the lactam carbonyl groups [53,54]. The electronic spectra of the
complexes showed an additional broad band tailing into the visible
region around 385–425 nm which was not seen in the free ligands.
This band was assigned to the ligand-to-metal charge-transfer tran-
sition. The expected characteristic d–d transitions in the visible re-
gion for the complexes were not detected even when concentrated
solutions were used. It was assumed that the bands were lost or
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at 385–425 nm as has been found for other Schiff base systems
[55–57].3.2.4. Molar conductivity of copper(II) complexes (2a–8a)
The molar conductivities of copper(II) complexes (2a–8a) in
DMSO solvent (4.0  l03 M) are given in Table 8. Conductance
measurements were not carried out for all of the complexes due
to their poor solubility. The conductance values measured (in the
range 0.40–14.45 S cm2 mol1) were too low to account for any
dissociation, hence the complexes were considered nonelectro-
lytes. 5a had a higher molar conductivity than the other complexes
due to the presence of two perchlorates anions in the complex.Fig. 2. Crystal structure of complex 2a. Displacement ellipsoids drawn at the 50%
probability level.3.2.5. Crystal structure of copper(II) complexes 2a and 8a
Crystal data and structure refinement of compounds 2a and 8a
are given in Table 2 and selected bond lengths and angles are pre-
sented in Table 9. The X-ray crystal structure and the crystal pack-
ing diagrams for 2a are shown in Figs. 2 and 3, respectively. From
Fig. 2 it was clearly observed that the Schiff base ligand 2 acted as a
monoanionic bidentate N, O-donor chelate and formed a neutral,
mononuclear, four coordinated complex [58]. Two MeOH mole-
cules and one DMSO molecule are also present within the asym-
metric unit. The ligand coordinated to the copper(II) ion via the
phenolic oxygen (at C15) and the nitrogen of the imine bond as ex-
pected [59,60]. The copper atom was surrounded by a N2O2 donor
set formed by the phenolic oxygens: Cu1–O20 = 1.915(3) and Cu1–
O1 = 1.916(3) Å and the nitrogen of azomethines from two ligand
molecules: Cu1–N28 = 1.964(3), Cu1–N9 = 1.975(3) Å. In all of the
four copper-ligand bond distances, the bond distances between
Cu–N are significantly longer than those of Cu–O bonds. Elongated
Cu–N bonds have also been observed for other Schiff base com-
plexes [61]. The largest distortion from regular square planar
geometry is shown in the trans O–Cu–N angles [145.69(11) and
140.36(11)]. In similar structures the geometry around the metal
centre was also considered as distorted square planar coordination
with significant tetrahedral distortion [62–68]. Due to the coordi-
nation of the metal ion to the phenolic oxygen, reduced bond dis-
tances were observed for coordinated C–O [O1–C2 = 1.329(4) Å]
compared to non-coordinated C–O [O4–C4 = 1.359(4) Å] bond
lengths.Table 9
Selected bond lengths (Å) lengths and angles () for complexes 2a and 8a.
(2a) Bond lengths (Å) (2a) Bond angles ()
Cu(1)–O(20) 1.915(3) O(20)–Cu(1)–O(1) 95.10(11)
Cu(1)–O(1) 1.916(3) O(20)–Cu(1)–N(28) 95.20(12)
Cu(1)–N(28) 1.964(3) O(1)–Cu(1)–N(9) 94.61(11)
Cu(1)–N(9) 1.975(3) N(28)–Cu(1)–N(9) 98.01(12)
O(1)–C(2) 1.329(4) O(1)–Cu(1)–N(28) 145.69(11)
C(4)–O(4) 1.359(4) O(20)–Cu(1)–N(9) 140.36(11)
O(20)–C(21) 1.310(4) C(2)–O(1)–Cu(1) 127.8(2)
C(27)–N(28) 1.310(4) C(8)–N(9)–Cu(1) 123.0(2)
N(28)–C(29) 1.441(4) C(10)–N(9)–Cu(1) 119.0(2)
O(20)–C(21) 1.310(4) C(11)–C(10)–N(9) 121.9(3)
C(21)–O(20)–Cu(1) 125.9(2)
(8a) Bond lengths (Å) (8a) Bond angles ()
Cu(1)–O(1) 1.845(9) O(1)–Cu(1)–O(29) 101.5(4)
Cu(1)–O(29) 1.866(10) O(1)–Cu(1)–N(9) 93.1(4)
Cu(1)–N(9) 1.920(11) O(29)–Cu(1)–N(9) 139.5(5)
Cu(1)–N(37) 1.934(12) O(1)–Cu(1)–N(37) 133.2(5)
O(1)–C(2) 1.322(16) O(29)–Cu(1)–N(37) 92.9(5)
C(8)–N(9) 1.284(16) N(9)–Cu(1)–N(37) 104.3(5)
N(9)–C(10) 1.392(17) O(1)–Cu(1) 128.2(8)
C(8)–N(9)–Cu(1) 125.8(9)
C(30)–O(29)–Cu(1) 128.7(9)
C(36)–N(37)–Cu(1) 126.6(10)The two quinolinone moieties were arranged in cis rather than
trans positions [69]. Hence, there are potential p–p stacking inter-
actions where the centroid–centroid distance is 3.485(4) Å (though
the slippage is 0.884 Å) between the ring C31–C36 and its symme-
try equivalent generated by the symmetry operation x, y, 1  z
[70]. This arrangement is complemented by centrosymmetric
NH  O hydrogen bonded ring with a graph set notation of
R4,4(8) [71] which holds two adjacent complexes in a dimeric
arrangement. This hydrogen bonding motif is undertaken by only
one of the two quinolinone groups. The NH in the other quinoli-
none group makes a single NH  O hydrogen bond with the DMSO
solvent whilst the lactam carbonyl (O14) makes an O  HO hydro-
gen bond with the uncoordinated [72] phenolic oxygen (O4). Inter-
molecular hydrogen bonds with solvent molecules extend the
hydrogen bonding network into three dimensions, assisting in sta-
bilising the crystal structure [73]. These hydrogen bonds are shown
in Table 10.
The individual metal complexes are stabilised by the formation
of two adjacent six-membered chelate rings [74]. Both rings are al-
most planar with Cu1 lying 0.095 Å off the plane defined by N9, C2,
C7, C8, O1 but lying 0.278 Å from the plane defined by O20, C21,
C26, C27, N28. The benzyl and quinolinone sections are not co pla-
nar, with the angle between the planes defined by the atoms form-
ing the aromatic rings (benzene ring C2 to C7) and (quinoline C10
to C19) being 52.9(2). In the other, second Schiff base ligand, the
equivalent angle is 30.3(2) which is significantly less twisted. This
second ligand also has the larger deviation of Cu1 from the plane
defined by the chelating ring. The bond lengths and bond angles
are almost identical in both chelate rings.
The crystal structure 8a (Figs. 4 and 5) also showed that the
mode of coordination of ligand 8 to copper(II) ion was via the phe-
nolic oxygen (at C15) and the nitrogen of the imine bond as ob-
served for the complex 2a. Selected bond lengths and bond
angles are presented in Table 11. The two quinolinone moieties
were again arranged in cis rather than trans positions and there
were two MeOH solvent molecules also present within the asym-
metric unit. The copper atom was surrounded by a N2O2 donor
set formed by the phenolic oxygens Cu1–O1 = 1.845(9) and Cu1–
O29 = 1.866(3) Å and the nitrogen of azomethines from two mole-
cules of ligand Cu1–N9 = 1.920(3) and Cu1–N37 = 1.934(3) Å. In all
Fig. 3. Crystal packing structure for complex 2a.
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tween Cu and N are significantly larger than those of Cu–O bonds.
However, these bond distances are slightly smaller than the bond
distances observed for complex 2a but can be regarded as normal
compared with the distances found in similar Schiff base com-
pounds [69]. 8a exhibited similar trans [139.5(5), 133.2(5)] and
bite [93.1(4), 92.9(5)] angles around the metal centre. The geom-
etry around the metal centre was also considered as distorted
square planar with significant tetrahedral distortion arrangement
as observed for complex 2a. The same centrosymmetric N–H  O
dimeric hydrogen bonding arrangement is present in 8a as in 2a,
but in 8a, both quinolinone groups have the R4,4(8) network. How-
ever the phenol ring substituents are all hydrocarbons so the net-
work exists as a stack propagated along the a axis as opposed to
the three-dimensional network found in 2a. The quinolinone rings
appear to stack in a way to allow p–p interactions but the closest
centroid–centroid distance is 3.719(9) Å. The hydrogen bonds are
listed in Table 11. The solvent molecules (MeOH), present in the
crystal structure do not extend the hydrogen bonding network be-
yond the stack being linked to one uncoordinated lactam carbonyl
(O17 or O45) each.Fig. 4. Crystal structure of complex 8a. Displacement ellipsoids drawn at the 40%
probability level.4. Biological studies
4.1. Antimicrobial activity of Schiff base ligands and their copper(II)
complexes
The anti-Candida activity of the ligands (2–14), their copper (II)
complexes (2a–14a) and the metal salts used in the synthesis of
the complexes is given in Table 12 expressed as MIC50 values (a
minimal concentration required to inhibit a 50% of cells growth).
No inhibition of growth was found for the free copper(II) salts.
Most of the quinolinone ligands and their copper(II) complexes dis-
played considerable activity against C. albicans, comparable to that
of a commercially available antifungal drug, Amphotericin B. If one
considers the activity of the ligands first, the most active ligands
are those with either two hydroxyl groups or one hydroxyl group
and an alkoxy group on the phenyl ring (4, 5, 6, and 7). However,Table 10
Hydrogen bond parameters for 2a.
D–H  A d(D–H) d(H  A) d(D  A) \(DHA)
O(4)–H(4)  O(1S)#1 0.84 1.83 2.659(4) 168.9
N(13)–H(13)  O(14)#2 0.81(4) 1.98(4) 2.793(5) 172(4)
O(23)–H(23)  O(33)#3 0.84 1.96 2.678(4) 142.5
N(32)–H(32)  O(3S)#4 0.93(4) 1.96(4) 2.867(4) 163(4)
O(1S)–H(1S)  O(14) 0.84 1.88 2.698(4) 165.9
O(2S)–H(2S)  O(1)#5 0.84 1.97 2.809(4) 175.1
Note: Symmetry transformations used to generate equivalent atoms: (i) x, y  1,
z  1; (ii) x + 1, y, z + 1; (iii) x, y, z  1; (iv) x + 1, y, z; (v) x, y + 1, z + 1.ligand 2 also has 2 hydroxy groups on the aromatic ring but they
are m- rather than o-dihydroxy. Of the halogen substituted com-
pounds, the activity of the fluoro-derivative was considerable bet-
ter than that of the iodo-, bromo- or chloro- analogues. A similar,
trend was also reported by Kalkhambkar et al. in their antimicro-
bial activity of a series of halogenated (F, Cl and Br) quinolin-
2(1H)-one and coumarin derivatives where the fluoro-derivatives
showed excellent activity compared to the corresponding chloro
and bromo derivatives. Despite these findings, it is difficult to
identify a structure activity relationship (SAR) with respect to
electronic and steric properties of a compound. It was found that
substitution of a methoxy group (15) in place of ethoxy group
(14) had little effect on activity indicating that the bulky nature
of the substituent has no effect on the activity of a compound at
this position. It may prove difficult to identify a real SAR when
the target of the ligands remained unidentified to date.
In general it can be seen that coordination to copper(II) resulted
in improved activity and all of the complexes, with the exception of
the fluoro-derivative, which exhibited greater activity (IC50 = 4–
51 lM) than their corresponding free ligands (IC50 = 10–80 lM).
The decreased activity of the complex 11a compared to that of li-
gand 11 could be attributed to its poor solubility but this should
also apply to complexes 9a–14a, as all of these complexes were
considerably less soluble than their respective free ligands. We
propose that complexation to the copper(II) ion may block the tar-
Fig. 5. Crystal packing structure for complex 8a.
Table 11
Hydrogen bond parameters for 8a.
D–H  A d(D–H) d(H  A) d(D  A) \(DHA)
N(44)–H(44)  N(44)#1 0.88 2.81 3.46(2) 132.0
N(44)–H(44)  O(45)#1 0.88 1.87 2.745(16) 176.3
N(16)–H(16)  O(17)#2 0.88 1.87 2.743(18) 171.8
O(58)–H(58)  O(17)#3 0.84 2.54 2.720(17) 93.4
O(60)–H(60)  O(45)#3 0.889(19) 1.84(3) 2.722(16) 169(14)
Note: Symmetry transformations used to generate equivalent atoms: x, y + 1, z,
x, y, z + 1.
4056 B.S. Creaven et al. / Inorganica Chimica Acta 363 (2010) 4048–4058get site of the ligand. The trend in activity of the complexes mirrors
those seen with the ligands, with complexes 4a–7a showing good
activity. In fact all of the complexes have good activity except the
fluoro- and iodo-derivatives, but as many of the complexes had to
be tested as suspensions, it is difficult to assign clearly defined
SAR’s.
The in vitro antibacterial activity of the most soluble Schiff base
ligands (2–8), their metal(II) complexes (2a–8a), the starting com-Table 12
Anti Candida activity of ligands and their copper(II) complexes expressed as MIC50.
Ligand MIC50 (lM) Complex MIC50 (lM)
1 36.9 – –
2 90.4 2a 8.2
3 95.6 3a 11.8
4 10.5 4a 4.5
5 17.1 5a 4.3
6 17.2 6a 4.3
7 17.6 7a 7.4
8 26.7 8a 19.8
9 29.1 9a 8.9
10 98.4 10a 8.6
11 18.2 11a 57.5
12 80.1 12a 51.5
13 >100 – –
14 >100 – –
Cu(II) salts >100 – –
Amphotericin B 0.61 – –pound 1 and the metal salts used in the synthesis of the complexes
were also determined. Surprisingly, none of the ligands or their
copper(II) complexes showed bacterial growth inhibition at maxi-
mum concentrations of 200 lM (data not shown). Inactivity
against both Gram-negative and Gram-positive species recorded
for the ligands and complexes together with their significant
anti-Candida activity suggested that they are highly selectivity
against fungal pathogens. The selectivity might be result from
the well established structural differences between fungal and bac-
terial cells [75], although the exact reasons remain as yet unclear.4.2. Anticancer activity of Schiff base ligands and their copper(II)
complexes
Selected compounds (2–8 and 2a–8a) were also screened for
their in vitro anticancer potential using the human hepatic carci-
noma cell line, Hep-G2. The anticancer activity of Schiff base li-
gands (2–8) and their Cu(II) complexes (2a–8a) were expressed
as IC50 ± S.E.M values as shown in Table 13. With the exception
of compounds 2 and 8, all of the tested metal-free ligands showed
moderate cytotoxicity (IC50 = 175–1000 lM). However, 2 and 8
were capable of killing cancer cells at low concentration
(IC50 = 39.67 ± 5.24 and 44.33 ± 4.70 lM). The solubility of all of
these ligands in complete culture media was very good and it is
very difficult to see a correlation between compounds 2 and 8 inTable 13
Anticancer activity of ligands and their copper(II) complexes expressed IC50 (lM)
values as measured using Hep-G2 cell line following 96 h exposure.
Ligand IC50 (lM) Complex IC50 (lM)
1 >1000 – –
2 39.67 ± 5.24 2a 47.00 ± 9.54
3 411.66 ± 7.26 3a 74.83 ± 8.91
4 >1000 4a 129 ± 16.26
5 398.33 ± 33.21 5a 17.90 ± 3.75
6 175.67 ± 12.20 6a 105.33 ± 25.41
7 521.67 ± 41.26 7a 53.17 ± 1.59
8 44.33 ± 4.70 8a 39.67 ± 10.18
Cisplatin 15.00 ± 2.65 – –
B.S. Creaven et al. / Inorganica Chimica Acta 363 (2010) 4048–4058 4057terms of a SAR. Given the presence of two t-butyl groups on the
aromatic ring (8), it is realistic to expect that it is quite lipophilic,
whilst the m-dihydroxy substituted ligand (2) should be quite
hydrophilic.
It is interesting to note that, most of the complexes (except 2a)
were found to be more active (IC50 = 17–129 lM) than the corre-
sponding free ligands. The overall order of the observed cytotoxic-
ity of the complexes was 5a > 8a > 2a > 7a > 3a 6a > 4a, with 5a
appearing to be the most potent and 4a, the least potent. More
importantly, the cytotoxicity (IC50 = 17.90 ± 3.75 lM) of complex
5a was comparable to that of the commercially available drug cis-
platin (IC50 = 15.00 ± 2.65 lM).5. Conclusion
In conclusion, a number of the novel ligands and complexes
investigated here had a potent antifungal effect being capable of
inhibiting growth of C. albicans by 50% even at a concentration of
4 lM (4a, 5a and 6a). Hence, it could be concluded that although
these compounds did not show any significant antibacterial prop-
erties, they may well function as effective antifungal agents. More-
over, the copper(II) complex 5a was found to exhibit potent
cytotoxicity, suggesting that it may be useful to investigate this
agent more fully as a potential anticancer agent. Thus, the results
presented here suggested that in the future, the copper(II) com-
plexes of Schiff base ligands have good potential as therapeutic
agents.6. Supplementary material
CCDC 781723 and 781724 contain the supplementary crystallo-
graphic data for 2a and 8a. These data can be obtained free of
charge from The Cambridge Crystallographic Data Centre via
www.ccdc.cam.ac.uk/data_request/cif.
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